HO-3867
Based on 9 publication(s) in Google Scholar
HO-3867 is a selective and potent STAT3 inhibitor and shows good antitumor activity.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.67%
- No. CAS: 1172133-28-6
- Fòrmula: C28H30F2N2O2
- Peso molecular:464.55
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-103128
inS3-54A18STAT3 Inhibitor -
HY-14944
HomoharringtonineSTAT Inhibitor -
HY-N0174
CryptotanshinoneAutophagy Inducer -
HY-112288
C188-9STAT3 Inhibitor -
HY-B0069
FludarabineDNA Synthesis Inhibitor -
HY-13818
StatticSTAT3 Inhibitor -
HY-100753
STAT3-IN-1STAT3 Inhibitor -
HY-B0497
NiclosamideAntihelminthic Agent -
HY-100493
BP-1-102STAT3 Inhibitor -
HY-15312
WP1066JAK2/STAT3 Inhibitor -
HY-15146
NSC 74859STAT3 Inhibitor -
HY-101853
STAT5-IN-1STAT5 Inhibitor
Publications Citing Use of MedChemExpress (MCE) HO-3867
More- J Adv Res. 2026 Jul 27:S2090-1232(26)00603-X.
- Cell Death Dis. 2021 Dec 20;13(1):16. [Abstract]
- JCI Insight. 2018 Sep 6;3(17):e120750. [Abstract]
- Biochem Pharmacol. 2025 Sep 6;242(Pt 2):117308. [Abstract]
- Int J Mol Sci. 2019 Aug 27;20(17):4202. [Abstract]
- J Biol Chem. 2024 Jun;300(6):107351. [Abstract]
- Invest New Drugs. 2025 Aug 4. [Abstract]
- J Cancer. 2020 Apr 6;11(13):3736-3744. [Abstract]
- Research Square Preprint. 2023 Jul 31.
Customer Validation & Images
-
RT-PCR
-
WB
-
Cell Migration/Invasion Assay
-
Cell Migration/Invasion Assay
-
Cell Proliferation/Viability Assay
Actividad biológica
Descripciòn
IC50 & Target
[1]|
STAT3 |
In Vitro
HO-3867 exhibit minimal toxicity toward noncancerous cells and tissues but induce apoptosis in ovarian cancer cells. HO-3867 inhibit cell migration/invasion and survival by inhibiting STAT3 phosphorylation[1].
BRCA-mutated ovarian cancer cells treated with HO-3867 exhibited a significant degree of apoptosis with elevated levels of cleaved caspase-3, caspase-7 and PARP[2].
HO-3867 shows good antitumor activity at the concentration of 2 μmol/L in PANC-1 and BXPC-3 cells. Importantly, it is also found that HO-3867 treatment significantly induced reactive oxygen species (ROS) production in human pancreatic cancer cell lines, inducing PANC-1 and BXPC-3 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 1172133-28-6
-
Appearance Solid
-
Peso molecular 464.55
-
Fòrmula C28H30F2N2O2
-
Color Light yellow to yellow
-
SMILES
O=C1/C(CN(CC2=CC(C)(C)N(O)C2(C)C)C/C1=C\C3=CC=C(F)C=C3)=C/C4=CC=C(F)C=C4
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
-
Cell Death Dis
Colorectal cancer-associated fibroblasts promote metastasis by up-regulating LRG1 through stromal IL-6/STAT3 signaling. [Abstract]2021 Dec 20;13(1):16. PMID: 34930899
HO-3867 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2021 Dec 20;13(1):16. [Abstract]
DLD1 and HCT-116 were cultured with control medium, CM from CAFs or treated with HO-3867 (3 μM) (STAT3 inhibitor) or pacritinib (JAK2 inhibitor), when cultured with CM from CAFs as indicated. Expression of LRG1 was subsequently analyzed by qRT-PCR.
HO-3867 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2021 Dec 20;13(1):16. [Abstract]
DLD1 and HCT-116 were cultured with control medium, CM from CAFs or treated with HO-3867 (3 μM) (STAT3 inhibitor) or pacritinib (JAK2 inhibitor), when cultured with CM from CAFs as indicated. Expression of LRG1 was subsequently analyzed by western blot.
-
JCI Insight
Ruxolitinib inhibits cyclosporine-induced proliferation of cutaneous squamous cell carcinoma. [Abstract]2018 Sep 6;3(17):e120750. PMID: 30185657
HO-3867 purchased from MedChemExpress. Usage Cited in: JCI Insight. 2018 Sep 6;3(17):e120750. [Abstract]
Proliferation assay of A431 cells exposed to ruxolitinib (10 μM); STAT1α-specific inhibitor, S14-95; and STAT3-specific inhibitor, HO-3867 (2.5 μM); alone and in combination, with and without 25 ng/ml CSA.
-
Biochem Pharmacol
Isoliquiritigenin inhibits the activation of the ANXA2/STAT3 pathway by down-regulating TAGLN2, thereby alleviating alcoholic fatty liver. [Abstract]2025 Sep 6;242(Pt 2):117308. PMID: 40921221 -
Int J Mol Sci
Hydrogen Sulfide Prevents Elastin Loss and Attenuates Calcification Induced by High Glucose in Smooth Muscle Cells through Suppression of Stat3/Cathepsin S Signaling Pathway. [Abstract]2019 Aug 27;20(17):4202. PMID: 31461977 -
J Biol Chem
STAT3 activation of SCAP-SREBP-1 signaling upregulates fatty acid synthesis to promote tumor growth. [Abstract]2024 Jun;300(6):107351. PMID: 38718868 -
Invest New Drugs
Synergistic effects of the curcumin analog HO-3867 and olaparib in transforming fallopian tube epithelial cells. [Abstract]2025 Aug 4. PMID: 40760233 -
J Cancer
Circulating Neutrophils Predict Poor Survival for HCC and Promote HCC Progression Through p53 and STAT3 Signaling Pathway. [Abstract]2020 Apr 6;11(13):3736-3744. PMID: 32328178
HO-3867 purchased from MedChemExpress. Usage Cited in: J Cancer. 2020 Apr 6;11(13):3736-3744. [Abstract]
Cell migration rates of SMMC-7721 increased after co-cultured with circulating neutrophils, but decreased when treated with inhibitors of p53(Pifithrin-β) and STAT3(HO-3867) (15 μM).
HO-3867 purchased from MedChemExpress. Usage Cited in: J Cancer. 2020 Apr 6;11(13):3736-3744. [Abstract]
Number of invasion cells of MHCC-97H and SMMC-7721 increased after co-cultured with circulating neutrophils, but decreased when treated with inhibitors of p53(Pifithrin-β) and STAT3(HO-3867) (15 μM).
-
Solvente y solubilidad
In Vitro:
DMSO : ≥ 32 mg/mL (68.88 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (5.38 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Rath KS et al. HO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancer. Cancer Res. 2014 Apr 15;74(8):2316-27. [Content Brief]
[2]. Hu Y, et al. A novel STAT3 inhibitor HO-3867 induces cell apoptosis by reactive oxygen species-dependent endoplasmic reticulum stress in human pancreatic cancer cells. Anticancer Drugs. 2017 Apr;28(4):392-400. [Content Brief]
[3]. Tierney BJ et al. HO-3867, a STAT3 inhibitor induces apoptosis by inactivation of STAT3 activity in BRCA1-mutated ovarian cancer cells. Cancer Biol Ther. 2012 Jul;13(9):766-75 [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1526 mL | 10.7631 mL | 21.5262 mL | 53.8155 mL |
| 5 mM | 0.4305 mL | 2.1526 mL | 4.3052 mL | 10.7631 mL | |
| 10 mM | 0.2153 mL | 1.0763 mL | 2.1526 mL | 5.3816 mL | |
| 15 mM | 0.1435 mL | 0.7175 mL | 1.4351 mL | 3.5877 mL | |
| 20 mM | 0.1076 mL | 0.5382 mL | 1.0763 mL | 2.6908 mL | |
| 25 mM | 0.0861 mL | 0.4305 mL | 0.8610 mL | 2.1526 mL | |
| 30 mM | 0.0718 mL | 0.3588 mL | 0.7175 mL | 1.7939 mL | |
| 40 mM | 0.0538 mL | 0.2691 mL | 0.5382 mL | 1.3454 mL | |
| 50 mM | 0.0431 mL | 0.2153 mL | 0.4305 mL | 1.0763 mL | |
| 60 mM | 0.0359 mL | 0.1794 mL | 0.3588 mL | 0.8969 mL |
HO-3867 Related Classifications
HY-100453 Related Classifications
Powered by Bioz